Denali Therapeutics Inc (NASDAQ:DNLI) Major Shareholder Douglas K. Bratton Sells 122,077 Shares

Denali Therapeutics Inc (NASDAQ:DNLI) major shareholder Douglas K. Bratton sold 122,077 shares of the stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $23.94, for a total transaction of $2,922,523.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

DNLI opened at $23.70 on Wednesday. Denali Therapeutics Inc has a 1-year low of $12.39 and a 1-year high of $30.41. The company has a market cap of $2.50 billion, a price-to-earnings ratio of -10.77 and a beta of 1.88. The company’s fifty day moving average price is $25.23 and its two-hundred day moving average price is $21.76. The company has a current ratio of 12.70, a quick ratio of 12.70 and a debt-to-equity ratio of 0.12.

Denali Therapeutics (NASDAQ:DNLI) last posted its earnings results on Thursday, May 7th. The company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.02. Denali Therapeutics had a negative net margin of 825.96% and a negative return on equity of 46.48%. The company had revenue of $3.60 million during the quarter, compared to the consensus estimate of $5.93 million. As a group, equities analysts forecast that Denali Therapeutics Inc will post -2.44 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Baillie Gifford & Co. raised its stake in shares of Denali Therapeutics by 20.3% in the first quarter. Baillie Gifford & Co. now owns 9,129,752 shares of the company’s stock worth $159,861,000 after purchasing an additional 1,539,505 shares during the last quarter. Perceptive Advisors LLC bought a new stake in Denali Therapeutics during the first quarter worth $14,884,000. Norges Bank purchased a new stake in Denali Therapeutics in the 4th quarter valued at $10,862,000. Casdin Capital LLC lifted its stake in Denali Therapeutics by 92.3% during the 4th quarter. Casdin Capital LLC now owns 1,250,000 shares of the company’s stock valued at $21,775,000 after acquiring an additional 600,000 shares in the last quarter. Finally, Marshall Wace North America L.P. purchased a new position in Denali Therapeutics during the 4th quarter worth $6,932,000. 75.03% of the stock is owned by hedge funds and other institutional investors.

A number of research firms have issued reports on DNLI. Nomura Securities reissued a “buy” rating and issued a $35.00 price objective on shares of Denali Therapeutics in a report on Monday, March 9th. ValuEngine downgraded Denali Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, May 1st. TheStreet upgraded Denali Therapeutics from a “d+” rating to a “c-” rating in a report on Wednesday, May 20th. Zacks Investment Research cut shares of Denali Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, June 22nd. Finally, Morgan Stanley cut their price target on Denali Therapeutics from $30.00 to $28.00 and set an “overweight” rating on the stock in a report on Wednesday, April 15th. Four investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Denali Therapeutics currently has an average rating of “Buy” and a consensus target price of $29.91.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.

Further Reading: What is the accumulation/distribution indicator?

Insider Buying and Selling by Quarter for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with's FREE daily email newsletter.